Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Papers: 14 Feb 2016 - 21 Feb 2016
Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis.
Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis.
Health Care Resource Use and Cost Of Multiple Sclerosis in Slovakia: Results from the National Cross-Sectional Study.
Static posturography across the EDSS scale in people with multiple sclerosis: a cross sectional study.
Papers: 23 Oct 2015 - 30 Oct 2015
Do evoked potentials contribute to the functional follow-up and clinical prognosis of multiple sclerosis?
Papers: 31 Jul 2015 - 7 Aug 2015
Newly Identified Gait Patterns in Patient With Multiple Sclerosis May Be Related to Push-Off Quality.
Cross-disease transcriptomics: Unique IL-17A signaling in psoriasis lesions and an autoimmune PBMC signature.
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Papers: 22 May 2015 - 29 May 2015
Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS).
Olfactory dysfunction in patients with multiple sclerosis.
Papers: 31 Jul 2014 - 7 Aug 2014
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
Papers: 10 Oct 2015 - 17 Oct 2015
Astrocyte tissue factor controls CNS hemostasis and autoimmune inflammation.
Evaluation of Disability Progression as an Endpoint in Clinical Trials for Relapsing-Remitting Multiple Sclerosis (RRMS): Comparison of the Define and Confirm Studies.
Papers: 14 Aug 2015 - 21 Aug 2015
Cortical functional modifications following optic neuritis.
Papers: 8 May 2015 - 15 May 2015
Susac's syndrome: Leptomeningeal enhancement on 3D FLAIR MRI.
Histamine and Immune Biomarkers in CNS Disorders.
A Real-World Assessment of Annual Multiple Sclerosis Prevalence and Disease-Modifying Drug Treatment Rates Using an Administrative Claims Database.

Pages